



## **ASX ANNOUNCEMENT**

**3 November 2023**

### **Change of Company Auditor**

---

**IDT Australia Limited** (ASX: IDT) (the “Company”) advises that in accordance with ASX Listing Rule 3.16.3, RSM Australia Partners (“RSM”) have been appointed as the Company’s Auditors. This appointment follows the resignation of Grant Thornton Audit Pty Ltd as auditor of IDT and ASIC’s consent to the resignation.

The appointment of a new auditor follows a review of the Company’s external audit arrangements and the Board selected RSM based upon their reputation and experience.

In accordance with section 327C of the Corporations Act 2001, a resolution will be tabled at the Company’s 2023 Annual General Meeting to seek approval for the appointment of RSM as the Company’s auditor.

The Board of Directors would like to take this opportunity to thank Grant Thornton Pty Ltd for their past assistance and services to the Company.

Ends.../

Authorised by the Board of Directors of IDT Australia Limited.

**For further information, please contact the Company Secretary:**

Mark Licciardo - Acclime  
P: +61 3 8689 9997  
E: [m.licciardo@acclime.com](mailto:m.licciardo@acclime.com)

**About IDT**

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT’s facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.